Xenon Pharmaceuticals Stock Performance
| XENE Stock | USD 41.48 0.14 0.34% |
Xenon Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm maintains a market beta of 0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xenon Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xenon Pharmaceuticals is expected to be smaller as well. Xenon Pharmaceuticals right now maintains a risk of 2.04%. Please check out Xenon Pharmaceuticals semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Xenon Pharmaceuticals will be following its historical returns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Xenon Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, Xenon Pharmaceuticals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.34) | Year To Date Return (6.77) | Ten Year Return 505.55 | All Time Return 295.05 |
1 | Disposition of 14375 shares by Mortimer Ian of Xenon Pharmaceuticals at 45.03 subject to Rule 16b-3 | 12/05/2025 |
2 | The top 5 stock picks for biotech in 2026 William Blair - Fierce Biotech | 12/23/2025 |
3 | Xenon Pharmaceuticals Trading 3.8 percent Higher - Heres Why - MarketBeat | 12/31/2025 |
4 | Disposition of 40000 shares by Mortimer Ian of Xenon Pharmaceuticals at 7.49 subject to Rule 16b-3 | 01/02/2026 |
5 | Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference | 01/05/2026 |
6 | Acquisition by Mortimer Ian of 65000 shares of Xenon Pharmaceuticals subject to Rule 16b-3 | 01/09/2026 |
7 | Xenon Outlines Key Upcoming Milestones at the 2026J.P. Morgan Healthcare Conference | 01/12/2026 |
8 | Did Xenons Azetukalner NDA Timeline and Neuropsychiatric Pivot Just Reframe Xenon Pharmaceuticals Investment Narrative | 01/16/2026 |
9 | Xenon Pharmaceuticals Inc. Receives 54.82 Average Target Price from Analysts | 01/29/2026 |
10 | Stifel raises Xenon Pharmaceuticals stock price target to 66 on XEN1101 potential - Investing.com India | 02/09/2026 |
| Begin Period Cash Flow | 148.6 M | |
| Total Cashflows From Investing Activities | 165 M |
Xenon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 4,061 in Xenon Pharmaceuticals on November 17, 2025 and sell it today you would earn a total of 87.00 from holding Xenon Pharmaceuticals or generate 2.14% return on investment over 90 days. Xenon Pharmaceuticals is currently generating 0.0546% in daily expected returns and assumes 2.0387% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Xenon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xenon Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Xenon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 41.48 | 90 days | 41.48 | about 70.5 |
Based on a normal probability distribution, the odds of Xenon Pharmaceuticals to move above the current price in 90 days from now is about 70.5 (This Xenon Pharmaceuticals probability density function shows the probability of Xenon Stock to fall within a particular range of prices over 90 days) .
Xenon Pharmaceuticals Price Density |
| Price |
Predictive Modules for Xenon Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Xenon Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Xenon Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Xenon Pharmaceuticals is not an exception. The market had few large corrections towards the Xenon Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Xenon Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Xenon Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.10 | |
β | Beta against Dow Jones | 0.41 | |
σ | Overall volatility | 1.67 | |
Ir | Information ratio | 0.03 |
Xenon Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Xenon Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Xenon Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Net Loss for the year was (234.33 M) with loss before overhead, payroll, taxes, and interest of (265.21 M). | |
| Xenon Pharmaceuticals currently holds about 788.24 M in cash with (181.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66. | |
| Xenon Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Stifel raises Xenon Pharmaceuticals stock price target to 66 on XEN1101 potential - Investing.com India |
Xenon Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Xenon Stock often depends not only on the future outlook of the current and potential Xenon Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Xenon Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 77.9 M | |
| Cash And Short Term Investments | 626.9 M |
Xenon Pharmaceuticals Fundamentals Growth
Xenon Stock prices reflect investors' perceptions of the future prospects and financial health of Xenon Pharmaceuticals, and Xenon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xenon Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (45.44) % | ||||
| Current Valuation | 2.75 B | ||||
| Shares Outstanding | 77.28 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 5.73 X | ||||
| Price To Sales | 427.38 X | ||||
| Gross Profit | (265.21 M) | ||||
| EBITDA | (235.86 M) | ||||
| Net Income | (234.33 M) | ||||
| Cash And Equivalents | 788.24 M | ||||
| Cash Per Share | 12.66 X | ||||
| Total Debt | 9.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 57.86 X | ||||
| Book Value Per Share | 7.25 X | ||||
| Cash Flow From Operations | (181.39 M) | ||||
| Earnings Per Share | (3.89) X | ||||
| Market Capitalization | 3.21 B | ||||
| Total Asset | 798.14 M | ||||
| Retained Earnings | (899.47 M) | ||||
| Working Capital | 599.67 M | ||||
| Current Asset | 60.87 M | ||||
| Current Liabilities | 2.78 M | ||||
About Xenon Pharmaceuticals Performance
By analyzing Xenon Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Xenon Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xenon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xenon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.35) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.34) | (0.35) | |
| Return On Equity | (0.36) | (0.37) |
Things to note about Xenon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Xenon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xenon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (234.33 M) with loss before overhead, payroll, taxes, and interest of (265.21 M). | |
| Xenon Pharmaceuticals currently holds about 788.24 M in cash with (181.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66. | |
| Xenon Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Stifel raises Xenon Pharmaceuticals stock price target to 66 on XEN1101 potential - Investing.com India |
- Analyzing Xenon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xenon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Xenon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xenon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xenon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xenon Pharmaceuticals' stock. These opinions can provide insight into Xenon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Correlations Find global opportunities by holding instruments from different markets |